This year on EHA, we shared exciting new data on Imbruvica
®
(ibrutinib) in RESONATE-2
Services
Media Center
Watch professor Ghia reveal how results from up to 7 years of follow-up reinforce the ground-breaking advance in 1L CLL that Imbruvica represents.
[1]
Categories / tags
Imbruvica
See all related
CP-240988 - June 2021